Group One Trading’s 4D Molecular Therapeutics FDMT Stock Holding History

Group One Trading’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$26.6K	Sell	2,000 -8,000	-80%	-$77.9K	﹤0.01%	5825
2026 Q1	$93.1K	Buy	10,000 +5,900	+144%	+$51.3K	﹤0.01%	4802
2025 Q4	$30.8K	Sell	4,100 -1,500	-27%	-$15.2K	﹤0.01%	6004
2025 Q3	$48.7K	Buy	+5,600	New	+$33.5K	﹤0.01%	5991
2025 Q2	–	Sell	-5,700	Closed	-$18.4K	–	8113
2025 Q1	$18.4K	Sell	5,700 -14,500	-72%	-$68.3K	﹤0.01%	5871
2024 Q4	$113K	Buy	20,200 +19,100	+1,736%	+$150K	﹤0.01%	4421
2024 Q3	$11.9K	Sell	1,100 -3,500	-76%	-$58.1K	﹤0.01%	5522
2024 Q2	$96.6K	Sell	4,600 -1,000	-18%	-$25.1K	﹤0.01%	3993
2024 Q1	$178K	Buy	+5,600	New	+$143K	﹤0.01%	3657
2023 Q3	–	Sell	-1,000	Closed	-$18.1K	–	7826
2023 Q2	$18.1K	Buy	+1,000	New	+$18.4K	﹤0.01%	6051
2022 Q1	–	Sell	-700	Closed	-$15K	–	8221
2021 Q4	$15K	Buy	+700	New	+$17.2K	﹤0.01%	7133

Other funds holding FDMT

Jupiter Topco New York $245B AUM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Group One Trading's FDMT Position: Q2 2026 in Review

Group One Trading sold out of 4D Molecular Therapeutics (FDMT) in Q2 2026, closing a stake of 1,998 shares — an estimated $19.5K sold.

Group One Trading first reported a position in FDMT in Q4 2021 and held it in 8 quarters. The position peaked at $74.8K in Q4 2023. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

Group One Trading reported no remaining 4D Molecular Therapeutics position as of Q2 2026 after selling out during the quarter.
Group One Trading sold 1,998 4D Molecular Therapeutics shares in Q2 2026, an estimated $19.5K.
Group One Trading first reported a position in 4D Molecular Therapeutics in Q4 2021 and held it in 8 quarters.
Group One Trading's 4D Molecular Therapeutics position peaked at $74.8K in Q4 2023.
158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.